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Abstract
Background: Immunophenotyping has been implemented in the diagnosis of children with acute leukemia in 
Yogyakarta, Indonesia. The aim of this study was to determine whether expression of CD10 and/or CD34 could be used 
as additional prognostic markers for children with acute lymphoblastic leukemia (ALL) treated on the Indonesia ALL 
2006 protocol. 
Materials & Methods: Of 211 ALL patients immunophenotype was determined and related to clinical data. Patient 
outcome was calculated as overall survival and event free survival, in which events were defined as: induction failure, 
death or relapse. 
Results: In the overall patients cohort, combination of CD10 and/or CD34 expression is an independent favorable 
prognostic factor in both univariate and multivariate analyses. 
In B-lineage ALL expression of CD10, CD34 and CD10+ and/or CD34+ were: 78%, 59% and 90% respectively. Although 
CD10, CD34 and the combined expression were associated with favorable outcome in the overall cohort, none of these 
parameters remained a significant independent risk factor after multivariate analysis in B-lineage leukemia.
In T-lineage leukemia, expressions of CD10, CD34 and CD10+ and/or CD34+ were: 30%, 21% and 49% respectively. 
Co-expression of CD10 and/or CD34 in this subgroup was a significant favorable prognostic factor in both univariate 
and multivariate analysis.
Conclusion: In our Indonesian population CD10 expression alone and in combination with CD34 expression are 
prognostically significant positive parameters.
Keywords: immunophenoyping, childhood leukemia, Acute Lymphoblastic Leukemia, CD10 , CD34, clinical outcome, 
Indonesia, developing country, Yogyakarta
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Introduction
Immunophenotyping of abnormal hematological cells is very 
useful for the diagnosis, classification, cost-effective treatment 
and prognostic evaluation in patients with hematological 
malignancies. [1-5] CD10 and CD34 are surface markers that have 
been reported to have prognostic relevance in childhood acute 
lymphoblastic leukemia (ALL), but the results were conflicting 
[6-10].
CD10 was originally known as common ALL antigen (cALLA). 
It was one of the first markers to identify acute leukemia in 
children. In the hematopoietic system, CD10 regulates stromal 
dependent B lymphopoiesis. The majority of B-lineage ALL 
cases expressed CD10. However, expression of CD10 has also 
been reported in other types of leukemia [11,12]. In B-lineage 
ALL, the percentage of cells expressing CD10 decreases in more 
mature forms [1,2]. Positive CD10 expression was associated 
with favorable clinical outcome [13]. In addition, lower white 
blood cell count (WBC), younger age, and subtype FAB L1 were 
associated with higher expression of CD10 [14]. Results of CD10 
expression vary among different studies, ranging from 68% to 
96% in B-lineage ALL, and 18% - 45% in T-lineage ALL (Table 1). 
CD34 is a human stage-specific hematopoietic differentiation 
antigen, and expressed in early-undifferentiated hematopoietic 
stem cells, both in lymphoid and myeloid pathways. In leukemic 
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cells, it remains expressed over several stages of lymphoid and 
myeloid maturation [15,16]. The clinical significance of CD34 
expression has been debated. It appears that the prognostic 
value depends on the type of leukemia and protocol used 
[7,17-19].
Studies on the combination of CD10 and CD34 expression in 
correlation with clinical outcome are limited. Dakka, et al. 2009, 
found that in B-lineage ALL, a combination of CD10+CD34+ co-
expression was found in 44% of cases, while CD10+CD34- was 
found in 34%. In T-lineage ALL, CD10-CD34- was found in the 
majority (76%) and was associated with worse prognosis with 
a 5 years survival rate of 22% [10]. To elucidate the relevance 
of the combined CD10 and CD34 expression as independent 
prognostic factor in children with ALL in Yogyakarta we 
related the expression of CD10, CD34 and the combination of 
both markers to clinical characteristics as well as to outcome. 
Material and Methods
Patients
From March 2006 to July 2010, 239 consecutive children 
with newly diagnosed with ALL were admitted to the Dr. 
Sardjito Hospital, Yogyakarta, Indonesia. Inclusion criteria for 
this study are: 0-14 years of age, no prior treatment, treated 
with Indonesia 2006 ALL protocol. Exclusion criteria are: 
prior treatment and mature-B ALL. Indonesia Protocol 2006 
has a 4-drug treatment in induction phase: Corticosteroid 
(Prednisone/ Dexamethasone), Vincristine, L-Asparaginase 
and Anthracyclin. In induction phase this protocol uses 4 
doses of daunorubicin (30 mg/m2) for SR and HR patients. In 
case of daunorubicin was not available it was replaced with 
doxorubicin in a dose of 20mg/m2. After induction patients 
received a consolidation and maintenance treatment. In 
HR patients, a re-induction course was inserted after the 
consolidation treatment. Otherwise, the SR and HR protocol 
consisted of the same drugs, doses and schedules.
From January 2006 we started to randomize prednisone 
and dexamethasone in standard risk only. Since May 2009 
high-risk patients were also randomized. Patients in the 
dexamethasone arm received prednisone 60 mg/m2/day 
during one week pre-phase, then dexamethasone 4 mg/
m2/day during induction and in blocks during maintenance 
for SR patients or dexamethasone 6 mg/m2/day during one 
week pre-phase, as well as in induction, re-induction and 
maintenance treatment blocks for HR patients. Patients in 
the prednisone arm received prednisone 60 mg/m2/day 
during pre-phase, then 40 mg/m2/day during induction and 
maintenance treatment blocks (SR patients) or prednisone 
40 mg/m2/day during pre-phase, induction, re-induction 
and in maintenance treatment blocks (HR patients).Patients 
who are not treated with this protocol were excluded from 
survival analysis.
Among these children, 211 cases met these inclusion 
criteria and complete data were available for both clinical 
data and immunophenotyping, including evaluation of CD10 
and CD34 expression. 
Morphology Diagnosis
Bone Marrow (BM) and Peripheral Blood smears were stained 
using May Grunwald–Giemsa Method, Periodic Acid-Schiff, 
Sudan Black and myeloperoxidase. Morphology diagnosis 
was based on FAB criteria.
Immunophenotyping
BM cells were also tested on 3 colors BD FACS-Calibur for 
immunophenotyping. The panel of monoclonal antibodies 
was: CD2, cytoplasmic CD3 (cCD3), CD7 for T-lineage ALL, 
CD10, CD19, CD22, cytoplasmic CD79a (cCD79a) for B-lineage 
ALL, CD13, CD33, cytoplasmic MPO (cMPO) and CD117 for 
myeloid lineage and CD45, IgG1, IgM, Tdt, and CD34 for non 
lineage. [1,2,11,20].
For membrane staining monoclonal antibodies were added 
(IgG1, CD2, CD7, CD10, CD13, CD19, CD22, CD33, CD34, CD117 
and CD45) to 30 µl of cell suspension in separate polystyrene 
tubes. This suspension was then incubated in the dark for 15 
minutes at room temperature. After incubation, 16.6 μlpara 
formaldehyde (4%) was added to the cell suspensions and 
incubated for 4 minutes at room temperature, in the dark. 
Then 1 ml lysing solution was added and lysed 10 minutes at 
room temperature, in the dark. Cells were then centrifuged 
1500 rpm for 5 minutes, cell pellets was washed twice, and 
re-suspended in 300-500 μl PBS. For Cytoplasmic staining 
(cIgG1, cCD79a, cCD3, cMPO and cTdT) cell suspensions were 
incubated for 15 minutes at room temperature then washed 
twice and re-suspended 300-500 μl of PBS. Run in the BD 
FACS-Calibur.
Study
B-lineage ALL T-lineage ALL
Reference
CD10  CD34 CD10 CD34
Pui, 1993 94 83 40 46 [7, 13]
Stella, 1995 - 70 - - [19]
Larson, 1995 - - - 50 [37]
Vanhaeke, 1995 - 60 - 40 [18]
Luna, 1997 68 - 29 - [23]
Cascavilla, 1997 - 86 - - [17]
Consolini, 1998 96 - 18 - [6]
Campana, 2000 95 - 45 - [2]
Basso, 2001 - 70 - 10 [22]
Bachir, 2009 91 74 21 42 [38]
Dakka, 2009 80 48 21 16 [10]
This study 76 53 27 24 -
Table 1. Literature overview on percentage of CD10 and CD34 
positive cells in various studies.
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Statistical analysis
The variables tested included, age, WBC, French-American-
British (FAB) subtype, risk classification, CD10, CD34 expression 
and Indonesia 2006 protocol with either prednisone or 
dexamethasone. For CD10 expression, a 10% threshold was 
selected to identify positive cases while for CD34 a 20% 
threshold was determined to be the optimal cut-off point.
The settings were based on literature and the frequency 
distribution of our data.  We selected the values of CD10 and 
CD34 that maximized the hazard ratio as the optimal the cut-
off values. These cut-off levels are similar to those in most of 
the mentioned studies.
The difference in frequencies between the CD10+ and 
CD10- or CD34+ and CD34- groups were examined using Chi-
square test. Most patients were treated with dexamethasone 
(161/211) whereas a prednisone protocol was used for the 
other patients. All hazard ratios calculated where corrected 
for the protocol (dexamethasone/prednisone) used.
Event-free survival (EFS) was calculated from date of start 
treatment to date of first event: induction failure, death, or 
relapse.  Overall survival (OS) was calculated from date of start 
treatment to date of death of any cause. Complete remission 
(CR) was determined at the end of induction treatment and 
defined as no detectable lymphoblast on peripheral blood or 
cerebrospinal fluid and less than 5% lymphoblasts in active 
haemopoiesis marrow and no physical signs of infiltrative 
leukemic cells anywhere. Induction failure defined as no 
complete remission. OS and EFS analysis was done using 
Kaplan-Meier method and compared using the Log rank test. 
Hazard ratios were estimated and multivariate models were 
fitted using Cox regression. A p-value less than 0.05 was used 
as level for statistical significance. All Variables with p<0.20 
in univariate analyses were included in multivariate analyses. 
All analyses were done in SPSS version 15.
EFS OS
n(%) HR (95% CI) p value HR 95%CI p value
Sex
Female 86(41) 1 1
Male 125(59) 1.5 0.92 – 2.38 0.11 0.65 0.41 – 1.04 0.07
Age at diagnosis
1 – 9 years 165(78) 1 1
<1 and  >10 years 46(22) 1.9 1.14 – 3.30 0.01 1.67 0.99 – 2.84 0.06
WBC at diagnosis
< 50.000/mm3 169(80) 1 1
> 50.000/mm3 42(20) 1.5 0.82 – 2.66 0.19 1.47 0.83 – 2.61 0.18
Classification*
Standard Risk 94(45) 1 1
High Risk 117(55) 2.2 1.22 – 4.02 0.01 1.86 1.06 – 3.26 0.03
FAB
ALL-L1 175(83) 1 1
ALL-L2 36(17) 1.2 0.64 – 2.09 0.63 0.82 0.43 – 1.57 0.55
Immunophenotyping
B-lineage ALL 178(84) 1 1
T-lineage ALL 33(16) 1.4 0.75 – 2.50 0.31 1.45 0.82 – 2.56 0.20
CD10 expression 
CD10+ 148(70) 1 1
CD10- 63(30) 1.9 1.19 – 3.15 0.01 2.13 1.33 – 3.41 0.002
CD34 expression
CD34+ 112(53) 1 1
CD34- 99(47) 1.1 0.72 – 1.89 0.52 1.25 0.78 – 2.00 0.36
Combination CD10 and CD34
CD10+CD34+ 84(40) 1 1
CD10+CD34- 64(30) 0.9 0.47 – 1.67 0.71 0.91 0.48 – 1.72 0.78
CD10-CD34+ 28(13) 1.4 0.66 – 2.95 0.39 1.43 0.67 – 3.03 0.36
CD10-CD34- 35(17) 2.2 1.18 – 4.15 0.01 2.81 1.56 – 5.07 0.001
CD10- and CD34-
CD10+ and/or CD34+ 176(83) 1 1
CD10-CD34-   35(17)    2.2   1.27 – 3.75      0.01   2.73 1.65 – 4.53  <0.001
Table 2. Univariate cox-regression analysis of event free survival and overall survival in the total ALL patient group
*Risk Classification based on NCI criteria; HR: Hazard Ratio was calculated with correction for protocol used
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Results
From 239 patients, 28 patients were excluded (12 patients 
used Wijaya Kusuma-2000 protocol, 5 had treatment before, 
4 refused to treat, 3 patients were non conclusive, 3 got 
suboptimal treatment, 1 patient aged more than 15 years). Two 
hundred and eleven patients were analyzed for clinical and 
biological features and their characteristics are summarized 
in Table 2. Death was the event was most frequently observed 
(n=50, 23.7%)'. This because abandonment is no longer 
considered to be an event. Fourteen patients (6.6%) relapsed 
and 4 patients (1.9%) failed in induction. In the whole patients 
cohort, EFS at 4 years was 58% ± 4% while OS at 4 years was 
84% ± 4%.
In the whole patient cohort, CD10 antigen was expressed 
in 148 (70%) of 211 patients tested. Relative frequency of 
positive CD10 expression was significantly higher (p<0.001)in 
SR stratification (83% of 94 patients) than in HR stratification 
(60% of 117 patients).
CD34 expression was found in 112 (53%) of 211 patients 
tested. This expression was also significantly associated with 
risk stratification (p<0.001); relative frequency of positive 
CD34 expression was found higher in SR group (67%) than 
in HR group (42%).
In addition to the effect of single CD10 expression, there 
was a significant (p<0.001) association between the combined 
CD10 and CD34 expression and risk stratification. Relative 
frequency of positive CD10 and positive CD34 co-expression 
was 56% of CD10+CD34+in the SR group compared to 27% 
of CD10+CD34+ in the HR group. CD10- and CD34- occurred 
in 6.4% of patients in SR group and 24.8% of patients in the 
HR group.
In univariate analysis for EFS in the whole cohort, age 
at diagnosis, risk classification, expression of CD10 and the 
combination of CD10 and CD34 were found to be statistically 
significant (Table 2). We also analyzed clinical associations with 
expression of CD10+ and/or CD34+ and thereby compared CD10-
CD34- versus all other groups (CD10+CD34+, CD10+CD34- and 
CD10-CD34+) since calculations including the four categories 
showed that only the double negatives significantly differed 
from the reference category of double positives. 
Multivariate analysis for EFS showed only age category 
and CD10-CD34- to be statistically significant. After correction 
for the protocol used hazard ratios were 2.11 (95% CI: 1.26 – 
3.54, p=0.004) for age category and 2.36 (95% CI: 1.39 – 4.02, 
p=0.002) for CD10-CD34-.
In univariate analysis for OS in the whole cohort, risk 
classification, expression of CD10 and the combination 
of CD10-CD34- were found to be statistically significant 
(Table 2). Multivariate analysis for OS showed that only age 
category and CD10-CD34- remained statistically significant. 
Hazard ratios were 1.87 (95% CI: 1.11 – 3.13, p = 0.02) for age 
category and 2.7 (95% CI: 1.65 – 4.54, p < 0.001) for CD10-
CD34- when corrected for protocol we use.
EFS for CD10+ patients was 63% ± 6% and for CD34- was 
44% ± 7%, p=0.004. For CD34+ EFS at 4 years was 60% ± 6% 
and EFS for CD34- was 55% ± 6%, p=0.403.
Kaplan-Meier analyses for OS showed that expression of 
CD10 and the combined expression CD10+ and/or CD34+ had a 
better prognosis (log-rank test p  < 0.001) while CD34+ alone 
did not reach significance (Figure 1). Patients with CD10+ had 
an OS at 4 years of 62% ± 6%, vs. CD10- of 40% ± 7%. for CD34+ 
alone this was 59% ± 6% vs. CD34- 53% ± 6%. OS at 4 years 
for the combined expression CD10+ and/or CD34+ was 61% ± 
5% vs. 31% ± 9% for CD10-CD34-
Figure 1. Overall survival of all children treated on the Indonesia 2006 ALL protocol. (A) Stratified by CD10 expression (CD10 
positive >10%; log-rank: p<0.001). (B) Stratified by CD34 expression (CD34 positive >20%; log-rank: p=0.223). (C) Stratified by 
expression of CD10 and/or CD34 (log-rank, p<0.001).
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B-lineage
For further analysis the patient group was stratified by lineage. 
In the B-lineage ALL group, the majority of samples were 
CD10+, 78% of 178 patients. Clinical and biological features of 
B-lineage patients and their characteristics are summarized 
in Table 3.
Clinical characteristics of B- and T-lineage ALL according 
to CD34 expression were shown in Table 4. CD10+ and/or 
CD34+ was found in 160/178 (90%).  Expression of CD10 and/
or CD34 was associated with risk classification, p=0.037. The 
minority (36%) of CD10+CD34+ patients was high risk, whereas 
the majority (67%) of CD10-CD34- patients was classified as 
high risk.
Variable B-lineage ALL, n=178 T-lineage ALL, n=33
CD10+ 
n (%)
CD10- 
n (%)
p value n(%)
CD10+ 
n (%)
CD10- 
n (%)
p value
Sex
 Male 100(56) 80 (80) 20 (20) 0.37 25(76) 6 (24) 19 (76) 0.16
 Female 78 (44) 58 (74) 20 (26) 8 (24) 4 (50) 4 (50)
Age
1-9 years 139(78) 107(77) 32 (23) 0.74 26(79) 10(39) 16 (61) 0.05
<1 &>10 years 39 (22) 31 (80) 8 (20) 7 (21) 0 (0) 7 (100)
WBC
< 50.000/ mm3 148(83) 115 (78) 33 (22) 0.90 21(64) 8 (38) 13 (62) 0.20
> 50.000/ mm3 30 (17) 23 (77) 7 (23) 12(36) 2 (17) 10 (83)
FAB
 L1 145(82) 115 (79) 30 (21) 0.23 30(91) 8 (27) 22 (72) 0.15
 L2 33 (18) 23 (70) 10 (30) 3 (9) 2 (67) 1 (33)
Risk*
 SR 94 (53) 78 (83) 16 (17) 0.07 0 0 (0) 0 (0) -
 HR 84 (47) 60 (71) 24 (29) 33 10 (30) 23 (70)
Table 3. Clinical characteristics of B- and T-lineage ALL according to CD10 expression
B-lineage ALL, n=178 T-lineage ALL, n=33
CD34+ 
n (%)
CD34- 
n (%)
p 
value
CD34+ 
n (%)
CD34- 
n (%)
p value
Sex
 Male      100(56) 55 (55) 45 (45) 0.22 25(76) 7(28) 18(72) 0.09
 Female     78 (44) 50 (64) 28 (36) 8 (24) 0 (0) 8(100)
Age
 1-9 years      139(78) 86 (62) 53 (38) 0.14 26(79) 5 (19) 21(81) 0.59
<1 &>10 years 39 (22) 19 (49) 20 (51) 7 (21) 2 (29) 5 (71)
WBC
<50.000/ mm3 148(83) 88 (60) 60 (40) 0.78 21(64) 5 (24) 16(76) 0.63
>50.000/ mm3 30 (17) 17 (57) 13 (43) 12(36) 2 (17) 10(83)
FAB
 ALL-L1 145(82) 84 (58) 61 (42) 0.55 30(91) 6(20) 24(80) 0.59
 ALL-L2 33 (18) 21 (64) 12 (36) 3 (9) 1 (33) 2 (67)
Risk*
 SR 94 (53) 63 (67) 31 (33) 0.02 0 0 (0) 0 (0) -
 HR 84 (47) 42 (50) 42 (50) 33(100) 7 (21) 26(79)
*Risk Classification based on NCI criteria
*Risk Classification based on NCI criteria
Table 4. Clinical characteristics of B- and T-lineage ALL according to CD34 expression
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In univariate analyses for EFS using Cox regression was shown 
in Table 5. Univariate analysis for OS, was presented in Table 6. 
In a univariate analysis for OS, we found that female patients 
in B-ALL, have almost twice higher chance to have a worse 
prognosis (Table 6). The same factors were found to be the 
only significant predictors for survival in the multivariate 
analyses in this subgroup.
In Kaplan Meier analysis, patients with CD10 expression had 
a higher better prognosis, although not statistically significant. 
EFS at 4 years was 61% ± 6% and CD10- was 49% ± 9%, p=0.084. 
For CD34, Kaplan-Meier analysis showed that patients with 
CD34+ expression had a similar survival compared to patients 
who were CD34-.Survival of CD10+ and/or CD34+ was 71% ± 
12% vs. CD10-CD34- was29% ±  13%, p=0.037. Overall survival 
curves are shown in Figure 2A, 2B and 2C.
T-lineage
CD10 expression in T-ALL was 30% and CD10- was a majority 
Variables
B-lineage ALL, n=178 T-lineage ALL, n=32
n HR (95% CI) p n HR (95% CI) p
Sex
 Female   78 1 8 1
 Male 100 1.79 1.05–3.06 0.03 24 0.76 0.23–2.99 0.76
Age at diagnosis (years)
 1 – 9 years 139 1 25 1
<1 and  >10 years 39 1.70 0.93-3.11 0.09 7 3.76 1.22 –11.6 0.02
WBC at diagnosis
< 50.000/ mm3 148 1 21 1
> 50.000/ mm3 30 1.18 0.57–2.47 0.65 11 1.90 0.60 –5.95 0.27
Classification*
 Standard Risk 94 1
 High Risk 84 2.12 1.14–3.97 0.02 32
FAB
 ALL-L1 145 1 29 1
 ALL-L2 33 1.10 0.58–2.10 0.77 3 2.46 0.54 –11.2 0.24
CD10 expression 
 CD10+ 138 1 10 1
 CD10- 40 1.60 0.90–2.85 0.11 22 3.73 0.82 –17.0 0.09
CD34 expression
 CD34+ 105 1 7 1
 CD34- 73 1.16 0.68–1.99 0.59 25 0.75 0.21 –2.73 0.66
Combination CD10 and CD34
 CD10+CD34+ 83 1 1 Numbers are too small to analyze
 CD10+CD34- 55 1.07
1.42
1.91
0.56–2.05 0.85 9
 CD10-CD34+ 22 0.63-3.23 0.40 6
 CD10-CD34- 18 0.90–4.20 0.11 16
CD10- and CD34-
 CD10+ and/or CD34+ 160 1 16 1
 CD10-CD34- 18 1.77 0.86-3.64 0.12 16 3.2 0.96 –10.5 0.06
Table 5. Univariate cox-regression analysis of event free survival in the B- and T-lineage ALL patient group
*Risk Classification based on NCI criteria; HR: Hazard Ratio was calculated with correction for protocol 
used. One patient was excluded from the analysis in the T-lineage group because this patient was treated with 
SR protocol.
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Table 6. Univariate cox-regression analysis of overall survival in the B- and T-lineage ALL patient group
*Risk Classification based on NCI criteria; HR: Hazard Ratio was calculated with correction for protocol used. One 
patient was excluded from the analysis in the T-lineage group because this patient was treated with SR protocol.
Variables
B-lineage ALL, n=178 T-lineage ALL, n=32
n HR (95% CI) p n HR (95% CI) p
Sex
 Female 78 1 8 1
 Male 100 0.53 0.31 – 0.91 0.02 24 1.09 0.35 – 3.42 0.89
Age at diagnosis (years)
 1 – 9 years 139 1 25 1
<1 and  >10 years 39 1.36 0.73 – 2.54 0.33 7 3.56 1.25 – 10.2 0.02
WBC at diagnosis
< 50.000/ mm3 148 1 21 1
> 50.000/ mm3 30 1.08 0.52 – 2.24 0.83 11 2.24 0.78 – 6.42 0.14
Classification*
 Standard Risk 94 1
 High Risk 84 1.71 0.94 – 3.08 0.08 32
FAB
 ALL-L1 145 1 29 1
 ALL-L2 33 0.86 0.43 – 1.70 0.66 3 1.01 0.13 – 7.71 0.99
CD10 expression 
 CD10+ 138 1 10 1
 CD10- 40 1.59 0.89 – 2.83 0.12 22 9.91 1.30 – 75.8 0.03
CD34 expression
 CD34+ 105 1 7 1
CD34- 73 1.13 0.66 – 1.93 0.66 26 1.41 0.32 – 6.27 0.65
Combination CD10 and CD34
 CD10+CD34+ 83 1 1
 CD10+CD34- 55 1.02 0.53 – 1.94 0.96 9 Numbers are too small to 
 CD10-CD34+ 22 1.37 0.61 – 3.10 0.45 6 analyze
 CD10-CD34- 18 1.88 0.86 – 4.11 0.11 16
CD10- and CD34-
 CD10+ and/or CD34+ 160 1 16 1
 CD10-CD34- 18 1.78 0.87 – 3.67 0.12 16 5.89 1.63 –21.3 0.007
Figure 2. Overall survival of B-lineage ALL children treated on the Indonesia 2006 ALL protocol.  
(A)Stratified by CD10 expression (CD10 positive >10%; log-rank: p=0.082).  
(B) Stratified by CD34 expression (CD34 positive >20%; log-rank, p=0.529).  
(C) Stratified by expression of CD10 and/or CD34 (log-rank, p=0.058).
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70% of 33 patients. In T-lineage ALL expression of CD10 was 
found only in age 1-9 years old (p=0.049). In the T-lineage 
group analyses of the combination of CD10 and CD34 were 
restricted to the comparison of CD10-CD34- versus the rest as 
the sub group CD10+CD34+ only contained a single patient 
and was therefore too small to analyze. The final model only 
consisted of the independent risk variable WBC and CD10-
CD34-. Their hazard ratios corrected for the protocol were 1.65 
(95% CI: 1.05 – 2.60, p-value 0.03) for WBC and 1.98 (95% CI: 
1.98 – 1.28, p-value 0.002) for CD10-CD34-. One patient was 
excluded from the analysis, because the patient was treated 
according to the SR protocol.
In univariate analysis for EFS of T-lineage patients were 
presented in Table 5. In the multivariate analysis for EFS age 
at diagnosis was the only parameter that remained significant 
hazard ratio was 3.5 (95% CI: 1.14 – 10.4, p=0.04).
In univariate analysis for OS, age at diagnosis, CD10 
expression and the combination of CD10-CD34- expression 
were statistically significant (Table 6) In multivariate analysis, 
only CD10-CD34-found to be related to OS, with a hazard 
ratio after corrected to the protocol was 6.1 (95% CI: 1.7 – 
21.3, p-value 0.005).Overall survival analysis for CD10, CD34 
expression and the combination of CD10+ and/or CD34+ are 
shown in Figure 3A, 3B and 3C.
Discussion
We examined the expressions of CD10, CD34 and the 
combination of CD10 and CD34 both in B- and T-lineage 
ALL. Two hundred and eleven patients were analyzed for the 
correlation of both markers with the clinical and biological 
features of those patients. We also analyzed the prognostic 
significance of both markers in the Indonesian ALL-2006 
protocol.
A large percentage of children included abandoned treatment 
early (n=37, 17.5%). Sitaresmi et al. 2009, found that reasons 
for treatment refusal or abandonment were: financial and 
transport difficulties, beliefs about curability and side-effects, 
children’s refusal, and dissatisfaction with health-care providers 
[21].
Studies on the expression of CD10 and CD34, alone or in 
combination, as a prognostic factor, found discrepancies 
[6,7,10,10,22,23]. These discrepancies may be dependent 
upon sensitivity of the immunophenotyping, upon patient 
variables, or upon differences in treatment protocols. In this 
study, we found 84% B-lineage ALL and 16% T-lineage ALL. 
This result is similar to our previous study [24]. Compared 
to studies in high income and low-income countries our 
finding is relatively high for T-lineage ALL [25-35]. Expression 
of CD10 and CD34 also varies in different studies (Table 1). In 
these studies of B-lineage ALL, CD10 antigen was detected 
in 68-96% and CD34 expression was 48%-86%. In T-lineage 
ALL less patients expressed these markers; CD10 expression 
was 18-45% and CD34 was 10%-50%. Our result for CD10 and 
CD34 were in the lower range for both B- and T-lineage ALL as 
reported by others. The possible reasons for this may be the 
different cut off points for positivity (range in the literature 
5 – 20%). Another plausible explanation for the differences in 
CD10 and CD34 expression can be the different ethnicity and 
thereby different genetic backgrounds (Asian vs. European/
American) [22,36].
Overall patients
Studies on the significance of CD10 expression on outcome 
also showed various results in the literature. Pui et al., [13] and 
Consolini et al., [6] found that in their patient cohort CD10+ 
expression in B- and T-lineage ALL had no independent 
Figure 3. Overall survival of children with T-lineage ALL treated on the Indonesia 2006 ALL protocol.  
(A) Stratified by CD10 expression (CD10 positive >10%; log-rank, p=0.005).   
(B) Stratified by CD34 expression (CD34 positive >20%; log-rank, p=0.608).   
(C) Stratified by expression of CD10 and/or CD34 (log-rank, p=0.002).
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prognostic significance [6,13]. Our results showed that overall; 
CD10 expression had a significant better survival compared to 
CD10-. CD10 expression had a significant prognostic value in 
univariate analysis for OS and EFS. But in multivariate analysis 
for OS and EFS, this expression was no longer significant. 
The remaining independent prognostic factors were double 
negativity of CD10 and CD34 besides age at diagnosis and 
risk classification.
In addition, Pui et al., [7] found that the expression of CD34 
was correlated with several favorable features at diagnosis such 
as age between 1-10 years of age, white race, absence CNS 
leukemia, low serum LDH, CD10 expression and hyperdiploidy. 
In concordance with our study, CD34 was associated with 
standard risk stratification but had no significant impact on 
prognosis.
A study conducted by Dakka et al., found that the five years 
survival rate for the CD10−CD34− group was only 22% [10]. In 
our study, lack of both CD10 and CD34 expression was also 
related to worse prognosis; OS was 61% in the combination 
CD10+ and/or CD34+ group vs. 31% in the double negative 
group, p<0.001 (Figure 1C). 
B-Lineage 
A limited number of studies on CD10 have been done in 
developing countries. A Study of CD10 in Mexico showed 
no significant prognostic value, EFS of CD10+ cases was 78% 
and CD10- was 71% (p=0.6) [23]. A study in Morocco found 
that the 5-year survival rate of B-lineage ALL with CD10+ is 
higher than in CD10- cases [10]. This result is similar to our 
findings (Figure 2A).
A study conducted by Cascavilla et al., [17] showed that 
expression of CD34 antigen was frequently expressed in 
B-lineage ALL and had a positive prognostic factor in childhood 
ALL. In our study expression of CD34 was associated with SR 
group. Survival rate between CD34+ and CD34- patients were 
similar (Figure 2B).
Studies on co-expression of CD10 and CD34 were limited. A 
study in Morocco, found in B-lineage ALL, that the co expression 
was associated with 1-10 years of age at diagnosis, male and 
low WBC [10]. In our study, co-expression of CD10 and CD34 
was associated with SR group. In SR group expression of CD10 
and/or CD34 was 94% while in HR group was 75% (p<0.001).
The predictive value of the co-expression was less strong 
in B-ALL group, but that is still may be clinically relevant. 
However, further research will be needed to establish this. 
T-Lineage 
In T-lineage ALL, Han et al., [14] found that CD10 expression was 
associated with lower WBC. In addition, CD34- was correlated 
with T-lineage ALL as well as age over 10 years, CNS disease 
at diagnosis, and higher WBC. In a different study [8], CD34 
expression was associated with poor disease free survival 
and overall survival. A univariate analysis of T-lineage ALL in 
our study showed that age at diagnosis, CD10 expression and 
combination of CD10 and CD34 were significantly associated 
with OS. In multivariate analysis only combination of CD10- 
and CD34- remained as a significant poor prognostic factor, 
Hazard Ratio: 5.9, 95%CI: 1.6 – 21.3, p=0.007. In Kaplan-Meier 
analysis patients with CD10 expression in this T-lineage ALL 
group had a better survival (p=0.005). Although the sample 
size of our patients was limited, we found that in Kaplan 
Meier analysis, lack of CD10 and the combination of CD10- and 
CD34- in T-lineage ALL had a significantly worse prognosis 
(Figure 3A and 3C).
Lack of CD10 and CD34 had a negative significant prognostic 
value especially in both overall and in T-ALL patients, while 
in B-lineage ALL it was only borderline significant. This fact 
can be explained because the prevalence of CD10-CD34- was 
higher in the high-risk group, and all T-ALL cases were high 
risk (by definition criteria of the protocol).
In T-lineage patients, even though they are HR in particular 
the CD10+ patients and the combined CD10 and CD34 
expression have a relatively good prognosis. Hence, a special 
care should be taken for those who are in T-lineage group 
with no expression of CD10 and/or CD34.
Conclusion
In our Indonesian population of children with ALL we show 
that it is important to determine the expression of CD10 to 
better predict the treatment outcome. The expression of CD10 
and the combination of CD10 and/or CD34 had a significant 
better survival.
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